HEREDITARY ANGIOEDEMA MARKET ANALYSIS

Hereditary Angioedema Market is segmented By Type (Hereditary Angioedema Type I and Hereditary Angioedema Type II), By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI1292
Pages :175
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenge- Missed diagnosis or misdiagnosis

The market growth can be hampered due to factors such as frequent misdiagnosis of the condition. For instance, according to an article published by Everyday Health, Inc., in June 2020, people with HAE are often misdiagnosed as having another medical problem. About 40% of people with HAE are diagnosed within the first three years whereas almost 33% of people still face delays of 10 years or longer.

Market Opportunity - Product pipeline for treatment

Robust product pipeline for HAE treatments presents significant growth opportunities for market players. Companies are developing next-generation prophylactic and on-demand therapies, including oral drugs and subcutaneous injections, which enhance treatment adherence. With compounds like long-acting C1 inhibitors and kallikrein inhibitors, these innovations focus on self-administration and variable dosing, promising to improve the quality of life for HAE patients.